Related Experiment Video
Updated: Jun 21, 2026
10:29
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
Extrapulmonary small cell carcinoma (EPSCC): 10 years' multi-disciplinary experience at Charité
Sebastian Ochsenreither1, Simone Marnitz-Schultze, Achim Schneider
1Charité, Campus Benjamin Franklin, Department of Medicine III (Hematology and Oncology), Hindenburgdamm 30, 12200 Berlin, Germany. sebastian.ochsenreither@charite.de
Anticancer Research
|August 8, 2009
Summary
Extrapulmonary small cell carcinoma (EPSCC) treatment outcomes were analyzed. Multimodal therapy can prolong survival for locoregional disease, while distant metastatic EPSCC survival is similar to small cell lung cancer.
Area of Science:
- Oncology
- Neuroendocrine Tumors
Background:
- Extrapulmonary small cell carcinoma (EPSCC) is a rare, aggressive neuroendocrine tumor.
- Understanding EPSCC treatment and outcomes is crucial for rare cancer management.
Purpose of the Study:
- To retrospectively analyze therapy and outcomes for EPSCC patients.
- To evaluate survival differences based on disease stage.
Main Methods:
- Retrospective analysis of 28 EPSCC patients diagnosed between 1998-2007 at Charité Berlin.
- Assessment of disease stage, therapy, treatment response, progression, and survival.
Main Results:
- Median survival was 43 months for locoregional disease (LD) and 12 months for distant metastatic disease (ED).
- Four of seven LD patients receiving combined chemotherapy and local treatment achieved disease-free status.
- Primary sites included genitourinary, head and neck, gastrointestinal, breast, and unknown.
Conclusions:
- Multimodal therapy can significantly improve survival for patients with locoregional EPSCC.
- Overall survival for distant metastatic EPSCC is comparable to that of small cell lung cancer with distant metastases.
